http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112979659-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4985 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-506 |
| filingDate | 2021-02-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-07-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-07-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-112979659-B |
| titleOfInvention | Preparation and application of HIF-2 alpha small molecule inhibitor |
| abstract | The invention belongs to the technical field of medicines, and relates to an HIF-2 alpha small molecule inhibitor, a preparation method and application thereof. The HIF-2 alpha small molecule inhibitor is shown as the structural general formula I The invention relates to a compound and a stereoisomer, pharmaceutically acceptable salt, hydrate, solvate or prodrug thereof, wherein the compound is prepared by screening a pharmacophore and carrying out molecular docking by using molecular simulation drug design software MOE, and designing and synthesizing a series of compounds according to the dominant structure of final docking and the principle of electronic isostere. The HIF-2 alpha small molecule inhibitor provided by the invention has better application prospect in the aspect of preventing or treating cancer, especially glioma. |
| priorityDate | 2021-02-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 65.